Tahamtan Ahmadi

机构：Genmab (United States) · ORCID：0009-0007-5031-3792

发表论文 187 篇 · 总被引 16031 次 · h-index 42

代表论文

• Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (2023 · New England Journal of Medicine · 被引 585)
• Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study (2024 · The Lancet Haematology · 被引 166)
• Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial (2025 · Nature Medicine · 被引 145)
• Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma (2024 · New England Journal of Medicine · 被引 120)
• Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects (2025 · Journal for ImmunoTherapy of Cancer · 被引 15)
• μMap-FFPE: A High-Resolution Protein Proximity Labeling Platform for Formalin-Fixed Paraffin-Embedded Tissue Samples (2025 · Journal of the American Chemical Society · 被引 13)